67
Participants
Start Date
May 17, 2018
Primary Completion Date
December 21, 2018
Study Completion Date
December 21, 2018
TEZ/IVA
Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
IVA
Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
Placebo
Placebo matched to TEZ/IVA FDC
Placebo
Placebo matched to IVA
Hunter Medical Research Institute (HMRI), New Lambton Heights
Princess Margaret Hospital for Children, Perth
Lady Cilento Children's Hospital, South Brisbane
The Children's Hospital at Westmead, Westmead
Universitair Ziekenhuis Brussel - Campus Jette, Brussels
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
University of Copenhagen Rigshospitalet, Copenhagen
Groupe Hospitalier Pellegrin - Hôpital des Enfants, Bordeaux
Hôpital Necker - Enfants Malades, Paris
Universitaetsklinikum Koeln, Cologne
Universitaetsklinikum Essen, Essen
Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt
Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen, Giessen
Medizinische Hochschule Hannover, Hanover
Universitaetsklinikum Heidelberg, Heidelberg
Universitaetsklinikum Jena, Jena
Universitaetsklinikum Tuebingen, Tübingen
Our Lady's Children's Hospital, Dublin
University Hospital Limerick, Limerick
Klinika Mukowiscydozy, Oddział Chorób Płuc SZP ZOZ, Dziekanów Leśny
Inselspital - Universitaetsspital Bern, Bern
Kinderspital Zuerich, Zurich
Royal Hospital for Sick Children, Edinburgh
Leeds General Infirmary, Leeds
Royal Brompton Hospital, London
Nottingham University Hospital City Campus, Nottingham
Southampton General Hospital, Southampton
Vertex Pharmaceuticals Incorporated
INDUSTRY